Table 2 Clinical CAR trials targeting T cell malignancies

CD5

NCT03081910 (MAGENTA)

Baylor College of Medicine

CD28

None

Phase I

Recruiting

CD7

NCT04004637

PersonGen BioTherapeutics

Phase I

Recruiting

NCT04033302

Shenzhen Geno-Immune Medical Institute

Phase I/II

Recruiting

NCT03690011

Baylor College of Medicine

CD28

CRISPR/Cas9

CD7-editing

Phase I

Not yet recruiting

NCT02742727

PersonGen BioTherapeutics

CD28 and 4-1BB

NK-92 cells

Phase I/II

Unknown

CD4

NCT03829540

Stony Brook University

CD28 and 4-1BB

Phase I

Recruiting

CD30

NCT01192464

Baylor College of Medicine

EBV-specific CTL

Phase I

Active, not recruiting

NCT03383965

Immune Cell Inc

2^nd generation

Phase I

Recruiting

NCT02690545

UNC Lineberger Comprehensive Cancer Center

Phase I/II

Recruiting

[62]

NCT02259556

Chinese PLA General Hospital

4-1BB

Phase I/II

Recruiting

[63]

NCT02958410

Southwest Hospital, China

Phase I/II

Recruiting

NCT03049449

NCI

Phase I

Recruiting

NCT01316146

UNC Lineberger Comprehensive Cancer Center

CD28

Phase I

Active, not recruiting

[55]

NCT02917083 (RELY-30)

Baylor College of Medicine

CD28

Phase I

Recruiting

[64]

NCT04008394

Wuhan Union Hospital, China

3^rd generation

Phase I

Recruiting

NCT03602157

UNC Lineberger Comprehensive Cancer Center

CCR4 overexpression

Phase I

Recruiting

NCT02663297

UNC Lineberger Comprehensive Cancer Center

CD28

Phase I

Recruiting

TRBC1

NCT03590574

Autolus Limited

RQR8 safety mechanism

Phase I/II

Recruiting